BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 50, Issue 11, 2009, Pages 1837-1842

  Zenz, Thorsten ^a   Benner, Axel ^b   Dhrsen, Ulrich ^c   Drig, Jan ^c   Dhner, Hartmut ^a   Siffert, Winfried ^c   Stilgenbauer, Stephan ^a   Nckel, Holger ^c  

^a UNIVERSITY OF ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

BCL2; Chronic lymphocytic leukemia; Prognostic marker; Single nucleotide polymorphism (SNP)

Indexed keywords

ADULT; AGED; ARTICLE; BCL2 GENE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; GENE; GENETIC ANALYSIS; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

COHORT STUDIES; DISEASE PROGRESSION; GENE FREQUENCY; GENOTYPE; GERMANY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 71049131735     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903207530     Document Type: Article

References (16)

1. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
2. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: Prognostic signifi- cance. Cancer 1977;40:855-864.
3. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
4. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-4951.
5. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-1029.
6. Hamblin TJ. Predicting progression-ZAP-70 in CLL. N Engl J Med 2004;351:856-857.
7. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775. (Pubitemid 36514707)
8. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
9. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100: 1410-1416.
10. Nückel H, Frey UH, Bau M, et al. Association of a novel regulatory polymorphism (-938C4A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007;109:290-297.
11. Kaderi MA, Norberg M, Murray F, et al. The BCL-2 promoter (-938C4A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia. Leukemia 2008;22:339-343.
12. Majid A, Tsoulakis O, Walewska R, et al. BCL2 expression in chronic lymphocytic leukemia (CLL): Lack of association with the BCL2-938A4C promoter single nucleotide polymorphism (SNP). Blood 2008;111:874-877.
13. Rossi D, Rasi S, Capello D, et al. Prognostic assessment of BCL2 C938A polymorphism in chronic lmphocytic leukemia. Blood 2008;111:466-468.
14. Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3- 21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969-975.
15. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007;16:219-242.
16. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986;5:255-260.